We’ve been talking a lot about clinical trials recently. But did you know, clinical trials don’t only test drugs? Dr Katrin Hulme, from King’s College London, tells us about a new trial investigating the effectiveness of COMPASS, a talking therapy programme for people with MS.
Alistair Gamble is just weeks into an MS Society-funded PhD exploring ways to reduce the risk of PML, a rare but serious disease associated with some MS treatments. He tells us why he’s chosen to follow this path, and what he hopes to achieve for people with MS.
It takes a long time and lots of hard work to develop a new MS treatment. In 2019, ocrelizumab (brand name Ocrevus) became the first drug to be available for people with primary progressive MS on the NHS.
Trying to get to grips with the complicated science behind MS and coronavirus is challenging enough – but imagine how it feels if you’re 12 years old! The MS team at Queen Mary University London are here to help.
Sarah Rees is a member of our Research Network. She caught up with researcher and occupational therapist Colette Beecher (pictured above) to find out how her experiences with an MS treatment called HSCT inspired her PhD project.
This weekend we’re catching up with just a few of the hundreds of researchers presenting their latest results at MS Virtual 2020, the world’s biggest MS research conference. Today, Lubna Almouzain, a PhD student at University College London, tells us about the research on pregnancy and MS she’s presenting at the conference.
This year, many MS researchers have found themselves working from home. But that doesn’t mean they’re working alone. The world’s two biggest MS research conferences have joined forces to go virtual, giving researchers like Dr Veronique Miron from the University of Edinburgh the vital opportunity to share their results and collaborate.
Last week, our Stop MS Scientific Ambassador Professor Anna Williams was part of an international team of MS researchers who published a whirlwind review of recent progress in myelin repair research. We dived in so you don’t have to…
Passionate staff adapting to work remotely? Yes. Dedicated participants staying engaged from afar? Yes. Scientists publishing new papers? Yes. The MS STAT2 trial staff and participants have kept fighting to keep MS research progressing throughout the pandemic. Here’s how.